Grannus Therapeutics

📍 Indianapolis, United States🗓 Founded 2019👥 2 employees💰 Last funded Jan 2020
Biotechnology
LinkedIn
Founded in 2019, Grannus Therapeutics is a pre-clinical stage biotechnology company, focused on the development of small molecule inhibitors for specific isoforms of HSP90. Our lead program is focused on the development of a highly selective small molecule inhibitor of HSP90𝛽 for the treatment of multiple types of cancer. With this program, we have successfully engineered a molecule that selectively inhibits HSP90𝛽, potentially delivering the efficacy benefits of previous pan-inhibitors without their toxicity and dosing challenges.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

1 investor
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Grannus Therapeutics?
Grannus Therapeutics has 1 investor on record on gritt.io, including 1 early-stage backers.
When did Grannus Therapeutics last raise funding?
The most recent investment in Grannus Therapeutics recorded on gritt.io was in January 2020.
When was Grannus Therapeutics founded?
Grannus Therapeutics was founded in 2019.
What industry is Grannus Therapeutics in?
Grannus Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Grannus Therapeutics based?
Grannus Therapeutics is headquartered in Indianapolis, United States.